这是一篇来自已证抗体库的有关人类 CTLA 4 (CTLA 4) 的综述，是根据69篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合CTLA 4 抗体。
CTLA 4 同义词: ALPS5; CD; CD152; CELIAC3; CTLA-4; GRD4; GSE; IDDM12

赛默飞世尔
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类
赛默飞世尔CTLA 4抗体（eBioscience, 47-1529-42)被用于被用于流式细胞仪在人类样本上. J Immunother Cancer (2022) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 小鼠; 图 5e
赛默飞世尔CTLA 4抗体（eBioscience, 46-1529-42)被用于被用于流式细胞仪在小鼠样本上 (图 5e). J Autoimmun (2021) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类; 图 s3
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上 (图 s3). Eur J Immunol (2019) ncbi
小鼠 单克隆（14D3）
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
  • 免疫印迹; 人类; 图 s1
赛默飞世尔CTLA 4抗体（eBioscience, 14-1529)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 1) 和 被用于免疫印迹在人类样本上 (图 s1). Cancer Immunol Immunother (2017) ncbi
小鼠 单克隆（14D3）
  • 免疫组化-冰冻切片; 人类; 图 5b
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于免疫组化-冰冻切片在人类样本上 (图 5b). Am J Pathol (2016) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类; 图 3c
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上 (图 3c). J Allergy Clin Immunol (2017) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 猕猴; 图 2
赛默飞世尔CTLA 4抗体（eBioscience, 46-1529)被用于被用于流式细胞仪在猕猴样本上 (图 2). Nat Commun (2015) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类; 图 7
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上 (图 7). Haematologica (2016) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上. Sci Rep (2015) ncbi
小鼠 单克隆（14D3）
  • 抑制或激活实验; 人类; 图 7
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于抑制或激活实验在人类样本上 (图 7). Nat Commun (2015) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上. Hum Immunol (2015) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上. J Immunol (2014) ncbi
小鼠 单克隆（14D3）
  • 流式细胞仪; 人类
赛默飞世尔CTLA 4抗体（eBioscience, 14D3)被用于被用于流式细胞仪在人类样本上. Leukemia (2015) ncbi
BioLegend
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 6c
BioLegendCTLA 4抗体（BioLegend, 349 908)被用于被用于流式细胞仪在人类样本上 (图 6c). Adv Sci (Weinh) (2021) ncbi
小鼠 单克隆（BNI3）
  • 其他; 小鼠
BioLegendCTLA 4抗体（BioLegend, BNI3)被用于被用于其他在小鼠样本上. Nat Commun (2020) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 4a
BioLegendCTLA 4抗体（Biolegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 4a). Arthritis Res Ther (2020) ncbi
小鼠 单克隆（L3D10）
  • mass cytometry; 人类; 图 2b
BioLegendCTLA 4抗体（Biolegend, 349902)被用于被用于mass cytometry在人类样本上 (图 2b). Cell (2019) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 5a
BioLegendCTLA 4抗体（BioLegend, BNI3)被用于被用于流式细胞仪在人类样本上 (图 5a). J Exp Med (2018) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 2b,2c
BioLegendCTLA 4抗体（Biolegend, 349913)被用于被用于流式细胞仪在人类样本上 (图 2b,2c). Oncoimmunology (2017) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类
BioLegendCTLA 4抗体（biolegend, L3D10)被用于被用于流式细胞仪在人类样本上. Nature (2017) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 5
BioLegendCTLA 4抗体（BioLegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 5). Cytotherapy (2017) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 s3
BioLegendCTLA 4抗体（Biolegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 s3). Nature (2016) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 3
BioLegendCTLA 4抗体（BioLegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 3). Am J Transplant (2016) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 3c
BioLegendCTLA 4抗体（Biolegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 3c). Science (2016) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 3b
BioLegendCTLA 4抗体（BioLegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 3b). Eur J Immunol (2016) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类; 图 5
BioLegendCTLA 4抗体（Biolegend, L3D10)被用于被用于流式细胞仪在人类样本上 (图 5). J Autoimmun (2015) ncbi
小鼠 单克隆（L3D10）
  • 流式细胞仪; 人类
BioLegendCTLA 4抗体（Biolegend, L3D10)被用于被用于流式细胞仪在人类样本上. Blood (2014) ncbi
圣克鲁斯生物技术
小鼠 单克隆（F-8）
  • 免疫组化; 小鼠; 1:5000; 图 7d
圣克鲁斯生物技术CTLA 4抗体（Santa Cruz Biotechnology, sc-376016)被用于被用于免疫组化在小鼠样本上浓度为1:5000 (图 7d). JCI Insight (2020) ncbi
小鼠 单克隆（F-8）
  • 流式细胞仪; 小鼠; 图 1b
圣克鲁斯生物技术CTLA 4抗体（Santa Cruz, sc-376016)被用于被用于流式细胞仪在小鼠样本上 (图 1b). Braz J Med Biol Res (2016) ncbi
小鼠 单克隆（F-8）
  • 免疫组化-石蜡切片; 人类; 1:300; 图 3c
圣克鲁斯生物技术CTLA 4抗体（Santa Cruz, sc-376016)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:300 (图 3c). J Immunol Res (2016) ncbi
小鼠 单克隆（F-8）
  • 免疫组化-石蜡切片; 人类; 1:50; 图 2
圣克鲁斯生物技术CTLA 4抗体（Santa Cruz, SC-376016)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 2). Breast Cancer Res (2016) ncbi
小鼠 单克隆（F-8）
  • 免疫组化-石蜡切片; 人类; 1:400; 表 4
圣克鲁斯生物技术CTLA 4抗体（Santa Cruz, sc-376016)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (表 4). Oncotarget (2016) ncbi
艾博抗（上海）贸易有限公司
domestic rabbit 单克隆（CAL49）
  • 免疫组化; 小鼠; 1:500
艾博抗（上海）贸易有限公司CTLA 4抗体（Abcam, CAL49)被用于被用于免疫组化在小鼠样本上浓度为1:500. NPJ Breast Cancer (2021) ncbi
亚诺法生技股份有限公司
小鼠 单克隆（2F1）
  • 免疫细胞化学; 人类; 1:100; 图 1
亚诺法生技股份有限公司CTLA 4抗体（Abnova, H00001493-M06)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 1). EJNMMI Res (2016) ncbi
碧迪BD
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD Biosciences, 555853)被用于被用于流式细胞仪在人类样本上. J Clin Invest (2020) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 2e
碧迪BDCTLA 4抗体（BD Biosciences, 555854)被用于被用于流式细胞仪在人类样本上 (图 2e). Cell (2020) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 5s1e
碧迪BDCTLA 4抗体（BD, 560938)被用于被用于流式细胞仪在人类样本上 (图 5s1e). elife (2019) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1f
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 1f). Proc Natl Acad Sci U S A (2019) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 s3a
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 s3a). Cancer (2019) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 猕猴; 图 4a
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在猕猴样本上 (图 4a). J Virol (2019) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 3f
碧迪BDCTLA 4抗体（BD, BNI3)被用于被用于流式细胞仪在人类样本上 (图 3f). J Clin Invest (2018) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 3d
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 3d). J Exp Med (2018) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 5a
碧迪BDCTLA 4抗体（BD Pharmingen, BNI3)被用于被用于流式细胞仪在人类样本上 (图 5a). Sci Rep (2017) ncbi
小鼠 单克隆（BNI3）
  • mass cytometry; 人类; 图 2a
碧迪BDCTLA 4抗体（BD Biosciences, BN13)被用于被用于mass cytometry在人类样本上 (图 2a). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1c
碧迪BDCTLA 4抗体（BD, BNI3)被用于被用于流式细胞仪在人类样本上 (图 1c). Nature (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 s2b
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 s2b). Immun Ageing (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 2
碧迪BDCTLA 4抗体（BD Biosciences, BN13)被用于被用于流式细胞仪在人类样本上 (图 2). Clin Exp Immunol (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 猕猴; 图 4b
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在猕猴样本上 (图 4b). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 2e
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 2e). Am J Transplant (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 6d
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 6d). Cell Death Dis (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 表 1
碧迪BDCTLA 4抗体（BD Biosciences, BN13)被用于被用于流式细胞仪在人类样本上 (表 1). Cytometry A (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 表 3
碧迪BDCTLA 4抗体（BD Pharmingen, BNI3)被用于被用于流式细胞仪在人类样本上 (表 3). Brain Behav (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上. Int J Cancer (2017) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 s3a
碧迪BDCTLA 4抗体（BD, 561717)被用于被用于流式细胞仪在人类样本上 (图 s3a). PLoS Pathog (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1
碧迪BDCTLA 4抗体（BD, 555853)被用于被用于流式细胞仪在人类样本上 (图 1). PLoS Pathog (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 s1
碧迪BDCTLA 4抗体（BD Biosciences, 555855)被用于被用于流式细胞仪在人类样本上 (图 s1). J Clin Invest (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 st1
碧迪BDCTLA 4抗体（BD, 555853)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD PharMingen, 555855)被用于被用于流式细胞仪在人类样本上. Immunity (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; African green monkey; 图 1
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在African green monkey样本上 (图 1). J Immunol (2016) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1a
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上 (图 1a). PLoS ONE (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 2
碧迪BDCTLA 4抗体（BD Biosciences, 555853)被用于被用于流式细胞仪在人类样本上 (图 2). Retrovirology (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1b,e
碧迪BDCTLA 4抗体（BD, 561717)被用于被用于流式细胞仪在人类样本上 (图 1b,e). PLoS Pathog (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD, 555855)被用于被用于流式细胞仪在人类样本上. Cytometry A (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类; 图 1
碧迪BDCTLA 4抗体（BD Biosciences, BN13)被用于被用于流式细胞仪在人类样本上 (图 1). J Immunol (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; African green monkey; 图 s4a
碧迪BDCTLA 4抗体（BD Pharmigen, BN13)被用于被用于流式细胞仪在African green monkey样本上 (图 s4a). PLoS Pathog (2015) ncbi
小鼠 单克隆（BNI3）
  • 流式细胞仪; 人类
碧迪BDCTLA 4抗体（BD, BNI3)被用于被用于流式细胞仪在人类样本上. J Immunol (2015) ncbi
小鼠 单克隆（BNI3）
  • 免疫细胞化学; 人类
碧迪BDCTLA 4抗体（BD Biosciences, BNI3)被用于被用于免疫细胞化学在人类样本上. Eur J Immunol (2014) ncbi
小鼠 单克隆（BNI3）
  • 免疫印迹; 人类; 图 3
碧迪BDCTLA 4抗体（BD Biosciences, 555853)被用于被用于免疫印迹在人类样本上 (图 3). Mol Cell Biol (2014) ncbi
文章列表
  1. Ni H, Zhang H, Li L, Huang H, Guo H, Zhang L, et al. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. J Immunother Cancer. 2022;10: pubmed 出版商
  2. Kim G, Kim W, Lim S, Lee H, Koo J, Nam K, et al. In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Adv Sci (Weinh). 2021;8:2004973 pubmed 出版商
  3. Steenbrugge J, Vander Elst N, Demeyere K, De Wever O, Sanders N, van den Broeck W, et al. OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer. NPJ Breast Cancer. 2021;7:27 pubmed 出版商
  4. Khosravi Maharlooei M, Li H, Hoelzl M, Zhao G, Ruiz A, Misra A, et al. Role of the thymus in spontaneous development of a multi-organ autoimmune disease in human immune system mice. J Autoimmun. 2021;119:102612 pubmed 出版商
  5. Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed 出版商
  6. Tan E, Hopkins R, Lim C, Jamuar S, Ong C, Thoon K, et al. Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency. J Clin Invest. 2020;130:5817-5832 pubmed 出版商
  7. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed 出版商
  8. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed 出版商
  9. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 2020;22:88 pubmed 出版商
  10. Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8: pubmed 出版商
  11. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed 出版商
  12. Remmerswaal E, Hombrink P, Nota B, Pircher H, ten Berge I, van Lier R, et al. Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans. Eur J Immunol. 2019;49:694-708 pubmed 出版商
  13. Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing J, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019;116:609-618 pubmed 出版商
  14. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed 出版商
  15. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed 出版商
  16. Petrelli A, Mijnheer G, Hoytema van Konijnenburg D, van der Wal M, Giovannone B, Mocholí E, et al. PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. J Clin Invest. 2018;128:4669-4681 pubmed 出版商
  17. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed 出版商
  18. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed 出版商
  19. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed 出版商
  20. Paulsen E, Kilvaer T, Rakaee M, Richardsen E, Hald S, Andersen S, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother. 2017;66:1449-1461 pubmed 出版商
  21. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed 出版商
  22. Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed 出版商
  23. van der Geest K, Wang Q, Eijsvogels T, Koenen H, Joosten I, Brouwer E, et al. Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study. Immun Ageing. 2017;14:5 pubmed 出版商
  24. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed 出版商
  25. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed 出版商
  26. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed 出版商
  27. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed 出版商
  28. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed 出版商
  29. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed 出版商
  30. Oelsner S, Friede M, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235-249 pubmed 出版商
  31. Sumatoh H, Teng K, Cheng Y, Newell E. Optimization of mass cytometry sample cryopreservation after staining. Cytometry A. 2017;91:48-61 pubmed 出版商
  32. Mai T, Ma R, Li Z, Bi S. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer. Braz J Med Biol Res. 2016;49:e5620 pubmed 出版商
  33. Dyer W, Tan J, Day T, Kiers L, Kiernan M, Yiannikas C, et al. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016;6:e00516 pubmed
  34. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  35. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed 出版商
  36. Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman H, Larman T, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016;186:3225-3235 pubmed 出版商
  37. Miles B, Miller S, Folkvord J, Levy D, Rakasz E, Skinner P, et al. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016;12:e1005924 pubmed 出版商
  38. Chen H, Händel N, Ngeow J, Muller J, Huhn M, Yang H, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139:607-620.e15 pubmed 出版商
  39. Fromentin R, Bakeman W, Lawani M, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761 pubmed 出版商
  40. Ruibal P, Oestereich L, Lüdtke A, Becker Ziaja B, Wozniak D, Kerber R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100-4 pubmed 出版商
  41. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18:43 pubmed 出版商
  42. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed 出版商
  43. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed 出版商
  44. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  45. Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed 出版商
  46. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed 出版商
  47. Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity. 2016;44:406-21 pubmed 出版商
  48. Vargas Inchaustegui D, Demers A, Shaw J, Kang G, Ball D, Tuero I, et al. Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques. J Immunol. 2016;196:1700-10 pubmed 出版商
  49. Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer S. Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI Res. 2016;6:1 pubmed 出版商
  50. Paris R, Petrovas C, Ferrando Martinez S, Moysi E, Boswell K, Archer E, et al. Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE. 2015;10:e0144767 pubmed 出版商
  51. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed 出版商
  52. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed 出版商
  53. Scottà C, Fanelli G, Hoong S, Romano M, Lamperti E, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91-100 pubmed 出版商
  54. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed 出版商
  55. Fricke F, Beaudouin J, Eils R, Heilemann M. One, two or three? Probing the stoichiometry of membrane proteins by single-molecule localization microscopy. Sci Rep. 2015;5:14072 pubmed 出版商
  56. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed 出版商
  57. Inglis H, Danesh A, Shah A, Lacroix J, Spinella P, Norris P. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A. 2015;87:1052-63 pubmed 出版商
  58. Yukl S, Shergill A, Girling V, Li Q, Killian M, Epling L, et al. Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults. PLoS ONE. 2015;10:e0121290 pubmed 出版商
  59. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed 出版商
  60. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers J, et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J Autoimmun. 2015;59:53-60 pubmed 出版商
  61. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed 出版商
  62. Gideon H, Phuah J, Myers A, Bryson B, Rodgers M, Coleman M, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11:e1004603 pubmed 出版商
  63. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed 出版商
  64. Huss D, Mehta D, Sharma A, You X, Riester K, Sheridan J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84-92 pubmed
  65. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed 出版商
  66. Pegram H, Purdon T, van Leeuwen D, Curran K, Giralt S, Barker J, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415-22 pubmed 出版商
  67. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed 出版商
  68. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed 出版商
  69. Kloog Y, Mor A. Cytotoxic-T-lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1. Mol Cell Biol. 2014;34:978-88 pubmed 出版商